HB-0056

N/A

Report date: 2025/09/10 17:58:15

Base Information

Drug NameHB-0056
Drug Alias NameHB0056HB-0056
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Bispecific monoclonal antibody
Mechanisms of ActionAnti-Thymic stromal lymphopoietinInterleukin-11 inhibitors
TargetsThymic stromal lymphopoietinInterleukin-11
Therapy Area/IndicationsDermatitis, AtopicIdiopathic Pulmonary FibrosisPulmonary Disease, Chronic Obstructive +[4] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryNew ZealandMainland China
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesShanghai Huaota Biopharmaceutical Co LtdZhejiang Huahai Pharmaceutical Co Ltd
China Registration ClassClass 1 therapeutic biologic in China

Develop Information

Active CompaniesHuaBo Biopharm Co LtdShanghai Huaota Biopharmaceutical Co Ltd
Inactive CompaniesN/A
Active IndicationsDermatitis, AtopicIdiopathic Pulmonary FibrosisPulmonary Disease, Chronic Obstructive +[4] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A